49 research outputs found
Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD
No full textKey Points
Monoclonal antibody blockade of the common γ chain attenuates acute and chronic GVHD. Common γ-chain cytokines increase granzyme B levels in CD8 T cells, which are reduced upon CD132 blockade in vivo
Plots of observed versus expected DNA methylation values for SALL3, TWIST2 and C/EBPα methylation standards
No full text<p><b>Copyright information:</b></p><p>Taken from "Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform"</p><p>Nucleic Acids Research 2006;34(3):e17-e17.</p><p>Published online 7 Feb 2006</p><p>PMCID:PMC1361623.</p><p>© The Author 2006. Published by Oxford University Press. All rights reserved</p> () SALL3, () TWIST2 and () C/EBPα results. Trend lines and values are displayed for each plot. The non-linearity of the observed versus expected methylation values is most likely due to a PCR amplification bias
NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
No full textItem does not contain fulltext01 april 201
Assessment of DNA methylation in clinical CLL samples and a human lung cancer cell line treated with 5-aza-2′dC
No full text<p><b>Copyright information:</b></p><p>Taken from "Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform"</p><p>Nucleic Acids Research 2006;34(3):e17-e17.</p><p>Published online 7 Feb 2006</p><p>PMCID:PMC1361623.</p><p>© The Author 2006. Published by Oxford University Press. All rights reserved</p> () Methylation levels of TWIST2 in 19 primary CLL samples generated by Bio-COBRA and Southern blot. The correlation coefficient between the two data sets was 0.98. ( and ) Restriction digestions of SALL3 (B) and C/EBPα (E) in A549 cells treated with 5-aza-dC at six different concentrations for 72 h (concentrations are indicated at the top). ( and ) Bio-COBRA quantification of the restriction digestions shown in (B) and (E). As expected, low doses of the demethylating agent showed a pronounced effect in the DNA methylation status of the analyzed loci. ( and ) mRNA expression level of SALL3 (D) and C/EBPα (G). Three separate measurements were performed for each sample. For C/EBPα, the expression level measured in the untreated cell line was normalized to 1. For SALL3, the expression level detected at 0.10 µM was normalized to 1, since the untreated cell line shows no expression under the experimental conditions utilized in this study
Alterations in peripheral lymphocyte subsets under immunochemotherapy in stage IV SCLC patients: Th17 cells as potential early predictive biomarker for response
No full textUICC stage IV small-cell lung cancer (SCLC) is a highly aggressive malignancy without curative treatment options. Several randomized trials have demonstrated improved survival rates through the addition of checkpoint inhibitors to first-line platin-based chemotherapy. Consequently, a combination of chemo- and immunotherapy has become standard palliative treatment. However, no reliable predictive biomarkers for treatment response exist. Neither PD-L1 expression nor tumor mutational burden have proven to be effective predictive biomarkers. In this study, we compared the cellular immune statuses of SCLC patients to a healthy control cohort and investigated changes in peripheral blood B, T, and NK lymphocytes, as well as several of their respective subsets, during treatment with immunochemotherapy (ICT) using flow cytometry. Our findings revealed a significant decrease in B cells, while T cells showed a trend to increase throughout ICT. Notably, high levels of exhausted CD4+ and CD8+ cells, alongside NK subsets, increased significantly during treatment. Furthermore, we correlated decreases/increases in subsets after two cycles of ICT with survival. Specifically, a decrease in Th17 cells indicated a better overall survival. Based on these findings, we suggest conducting further investigation into Th17 cells as a potential early predictive biomarkers for response in patients receiving palliative ICT for stage IV SCLC
Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
No full text
